Abstract PD9-05: A tiered algorithm using mid-therapy ultrasound (US) response assessment and a novel gene expression signature (GES) improves the prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple-negative breast cancer (TNBC): Results from the ARTEMIS trial (NCT02276443)

Background: The heterogeneity of TNBC results in mixed responses to NAST: 30-60% of patients (pts) have a pCR to standard chemotherapy with an excellent prognosis. Several methods have been used to predict pCR, most yielding a positive predictive value (PPV) of no greater that 70%. To improve prediction of pCR to NAT, we hypothesized that we can integrate mid-treatment US with molecular profiling to generate a GES, thus reducing the need for...